Simanshu
@simanshu.bsky.social
BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial (NCT06625775) in patients with HER2+ and HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. Read the BBOT press release here:
June 12, 2025 at 9:52 PM
BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial (NCT06625775) in patients with HER2+ and HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. Read the BBOT press release here:
This publication describes how BBO-10203 disrupts the RAS–PI3Kα interaction without impairing insulin signaling, resulting in broad antitumor activity across multiple cancer models. It also shows enhanced efficacy in combination with other targeted agents.
June 12, 2025 at 9:52 PM
This publication describes how BBO-10203 disrupts the RAS–PI3Kα interaction without impairing insulin signaling, resulting in broad antitumor activity across multiple cancer models. It also shows enhanced efficacy in combination with other targeted agents.
Our collaborative efforts demonstrate the power of structure-guided drug discovery in tackling one of the most frequently mutated signaling axes in cancer.
June 12, 2025 at 9:52 PM
Our collaborative efforts demonstrate the power of structure-guided drug discovery in tackling one of the most frequently mutated signaling axes in cancer.
Our longstanding, cross-institutional journey from concept to clinic was powered by the dedication of many scientists from BridgeBio Oncology Therapeutics (BBOT), Lawrence Livermore National Laboratory, and the NCI RAS Initiative at Frederick National Laboratory for Cancer Research.
June 12, 2025 at 9:52 PM
Our longstanding, cross-institutional journey from concept to clinic was powered by the dedication of many scientists from BridgeBio Oncology Therapeutics (BBOT), Lawrence Livermore National Laboratory, and the NCI RAS Initiative at Frederick National Laboratory for Cancer Research.